Long-Term Extension, Open-Label Study of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder.
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2009
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 29 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.